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ABSTRACT
A n em ia  is a  com m o n  feature in abo u t 40%  of pa tien ts  a t the  m om ent of cance r d iagnos is  and  in m ore than half 
o f pa tien ts  on an tica nce r therapy. Therapeutic  a lte rnatives in cance r patien ts  w ith  a ne m ia  inc lude  substitu tion  
o f lacking a ge n ts , red b lood  cell tran s fus ions , and  e ry th ropo ies is -s tim u la ting  agen ts (ESA s). The adva n tag es of 
red b lood  cell trans fus ions  are rapid increase o f hem og lob in  conce n tra tion  and e ffectiveness in depend en t of the 
cause  o f anem ia. H ow ever, several adverse reactions m ay o ccu r a fter b lood  co m p o n e n t transfus ion. ESAs act 
th ro ugh  stim u la tion  o f e ry th ropo ie tin  receptors. U se  of ESAs reduces the need fo r red b lood  cell tran s fus ions , 
decreases the risk of pos t-trans fus ion  adverse reactions, and  im proves the  qua lity  o f life o f cance r patien ts  w ith 
chem otherapy-induced anemia. In accordance  w ith registered ind ications, ESA may be adm in istered in non-m yelo id 
cance r patien ts  w ith chem otherapy-indu ced  anem ia. T h rom boem bo lic  events and arterial hype rtension are know n 
risks of ESA treatm ent. If ESAs are used in accordance  w ith  currently app roved  ind ica tions and are not adm in istered 
w hen hem og lob in  (Hb) conce n tra tion  is 12 g /d L  o r above, there  is no obse rved unfavorab le  e ffect on survival or 
th ro m b o e m b o lic  risk. The adm in is tra tion  of RBC trans fus ions  w ith ou t de lay is justified  in patien ts  w ith  H b under 
7 -8  g /d L  an d /o r severe anem ia-re la ted  sym p to m s (even at h igher H b  levels) and the  need fo r im m ed ia te  Hb 
and sym p to m  im provem ent. The goa l o f ESA trea tm en t is m a in tenance of the  low est hem og lob in  concen tra tion  
needed to  avoid red b lood cell transfusion. ESAs m ay be used in patients with sym pto m atic  chem otherapy-induced 
ane m ia  and  H b  concen tra tion  at 10 g /d L  or below. There is no ind ica tion  fo r ESAs in patien ts  w ho are not receiving 
chem o the rapy  o r w h o  are receiv ing radiotherapy.
Key w ords: anem ia, chem othe rapy in duced anem ia, cancer, b lood  transfus ion, e ry th ropo ies is  s tim u la ting  agents 
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Anemia — morbidity, etiology, 
classification
Anemia (Lat. anaemia — comes from the Greek 
name anaimia, meaning lack of blood) is a reduction 
of blood’s ability to deliver oxygen to tissues and its 
oxygen-carrying capacity. Anemia very often accom­
panies cancers, disturbs the anticancer treatm ent and 
adversely impact on the patients’ quality of life (QoL).
Anemia occurs in approximately 40% of patients at 
cancer diagnosis and in more than half of patients un­
dergoing anticancer treatment. The influence of anemia 
on malaise and quality of life has been described since 
the 1970s, so it is very important to treat all symptomatic 
patients [1].
Table 1. Reference values o f the red cell system
W om en  M en
H e m o g lo b in  leve l 1 2 .5 -1 5 .5  g /d L  1 3 ,5 - 1 7 ,5  g /d L
RBC c o u n t 4 .2 - 5 .4  T/L 4 ,6 - 6 ,2  T/L
H e m a to c r it 3 7 - 4 7 %  4 0 - 5 4 %
M C V 8 0 - 9 4  fL
M C H C 3 2 - 3 8  g /d L
M C H 2 7 - 3 2  p g
R e tic u lo c y te  p e rc e n ta g e 5 -1 5 % o  (2 8 - 1 0 0  G/L)
R D W * 1 1 .5 -1 4 .5 %
*R ed b lo o d  cell v o lu m e  v a r ia t io n  (an isocytos is); M C V  —  m ean  co rp uscu la r v o l­
um e ; MCHC —  m ean co rpuscu la r h e m o g lo b in  co n c e n tra tio n ; MCH —  m ean cor­
puscu la r h e m o g lo b in ; RBC —  red b loo d  c o u n t; RDW —  red cell d is tr ib u tio n  w id th
In the prospective European Cancer Anaemia Sur­
vey (ECAS) [2], more than half of the 15,367 patients 
from 24 European countries developed anemia during 
anticancer treatment. A  similar observational POLCAS 
study [3] involving 999 patients from 13 Polish oncology 
centers provided almost identical results — anemia was 
found in more than half of the patients after treatm ent 
completion (most often cancer of the female reproduc­
tive system, lung cancer and testicular cancer). A  de­
crease in hemoglobin (Hb) levels correlated with a de­
cline in performance status (PS), but only one-third of 
anemic patients received treatment, the most frequently 
red cell concentrates (RCC) transfusion.
Abnormal hematopoiesis or too fast red blood cells 
breakdown, as well as, acute or chronic blood loss lead 
to decreased Hb level and the number of erythrocytes 
(red blood cells, RBCs) in the peripheral blood below 
the normal values (Table 1) [4, 5].
D epending on Hb level, anem ia is classified as: 
mild (Hb > 10 g/dL, but below the norm al value), 
moderate (Hb 8-10 g/dL), severe (Hb 6.5-7.9 g/dL) and 
life-threatening (Hb < 6.5 g/dL).
The most important causes of anemia are:
— deficiencies of:
• iron following bleeding in and out of the tumor 
or following surgery,
• folic acid due to malnutrition,
• vitam in B12 associated  w ith m alabsorption  
disorders (e.g. after gastrectomy, in gastrointes­
tinal neoplasms);
— immune (lymphomas, chronic lymphocytic leukemia, 
adenocarcinomas) and non-immune hemolysis (e.g. 
microangiopathic hemolytic anemia [MAHA] in 
mucus-producing tumors or prostate cancer — usual 
reticulocytes below 2%e);
— bone m arrow suppression after systemic use of 
cytotoxic drugs (especially nephrotoxic) or after 
irradiation > 20% of the bone marrow volume);
— erythropoiesis inhibition due to tumor infiltration 
of bone marrow;
— erythrophagocytosis in histiocytic lymphomas;
— erythropoiesis inhibition due to suppression of 
endogenous erythropoietin production (e.g. by cy­
tokines) or inappropriate iron utilization [the most 
common cause, i.e. functional iron deficiency, which 
gives a picture of anemia of chronic disease (ACD)]. 
A  healthy person has enough iron stores for up to
2-fold increase of erythropoiesis. Blood loss or impaired 
absorption leads to true iron deficiency with ferritin 
levels 30 ng/mL and transferrin saturation below 15%. 
Abnormal values of the above param eters are stand­
ard indications for iron preparations use. It should be 
remembered that in cancer patients, functional iron de­
ficiency is often observed, with ferritin level 800 ng/mL 
or less and transferrin saturation below 20% [5].
Based on the mean corpuscular volume, anemia 
could be classified as:
— microcytic (MCV < 80 fL) — with increased red 
cell distribution width (RDW), most often due to 
iron deficiency in chronic bleeding or sideroblastic 
anemia, with normal RDW  in the course of ACD 
and spherocytosis;
— normocytic (MCV 80-100 fL) in the course of ACD 
(most often), after chem otherapy or irradiation 
(iatrogenic), as a result of bone marrow infiltration, 
acute bleeding, in the initial stage of iron deficiency 
anemia, in mixed vitamin deficiencies, in kidney 
diseases, hypothyroidism;
— macrocytic (MCV > 100 fL) in hemolysis (often in 
lymphoproliferative diseases — late autoimmune 
hemolysis, after fludarabine, after incompatible 
blood transfusion), due to vitamin B12 and/or fo­
lic acid deficiency, in myelodysplastic syndromes, 
multiple myeloma, liver diseases, hypothyroidism, 
sideroblastic anemia and during the regeneration 
of the hematopoietic system after chemotherapy.
In addition to a low MCV, abnormal laboratory
parameters in iron deficiency include:
— RDW  — increased;
— number of hypochromic erythrocytes — increased;
— reticulocytes Hb content — decreased;
— iron concentration — reduced;
— ferritin concentration — low;
— transferrin saturation — low (Fe/TIBC < 20%);
— concentration of soluble transferrin receptors (sTfR) 
— increased;
— total iron binding capacity (TIBC) — increased.
Consequences of anemia in cancer 
patients
Anemia in cancer patients:
— worsens the quality of life;
— precludes the maintenance of the chemotherapy regimen, 
which directly affects the effectiveness of the therapy;
— reduces radiation-curability;
— has a negative prognostic impact;
— correlates with higher mortality (in particular in pa­
tients with lymphomas, head and neck cancers, lung 
cancer, cervical cancer, prostate cancer).
Diagnostics
Depending on patient’s general condition, before 
deciding on the treatm ent method, the tests should be 
perform ed to determine the etiology of anemia and 
to enable causative treatm ent and/or therapy with the 
lowest risk of adverse reactions.
The following diagnostic tests are recommended:
— complete blood count;





— folic acid concentration;
— vitamin B12 concentration
— fecal occult blood test (FOBT);
— param eters assessing renal function.




— direct antiglobulin test (CLL, lymphomas, prior 
autoimmune disease);
— testing for hemoglobinopathy.
When the cause of anemia in cancer patient is not de­
termined, it is classified as cancer induced anemia (CIA).
Treatment
In the management of anemia in cancer patients, 
causal treatm ent should be used when available and the 
diagnosed deficiencies should be corrected first (iron, 
vitamin B12, folic acid). If deficiencies correction does 
not bring the expected results and the anemia does 
not improve despite the anticancer treatm ent, ESA 
administration may be considered. RBC transfusions 
are reserved for the following situations: deficiencies 
correction has not brought the expected results, there 
are no indications for ESA, and the level of anemia does 
not allow the initiation or continuation of anticancer 
treatm ent or causes significant symptoms.
Iron supp lem enta tion
Criteria for starting iron supplementation are as fol­
low:
— anemia (8 < Hb < 10 g/dL) or
— absolute iron deficiency (ferritin < 100 ng/mL and 
transferrin saturation < 20%);
— relative iron deficiency (ferritin > 100 ng/mL and 
transferrin saturation < 20%) — iron should be 
administered before starting ESA.
While using ESA, iron levels should be monitored 
and supplemented as needed.
Contraindications to iron supplementation — ac­
tive infection, treatm ent with drugs with cardiotoxicity 
related to the generation of free oxygen radicals (anthra- 
cyclines, alkylating drugs and Vinca alkaloids).
Administration route
Due to frequently reduced iron absorption from the 
gastrointestinal tract in cancer patients, iron prepara­
tions should be administered intravenously.
Dosage
— 1000 ixg once or in divided doses, depending on the 
type of drug.
Red b lood cells concentra tes transfusion
Preparations containing red blood cells are:
— red cell concentrate (RCC) (packed red cells);
— leukocyte-depleted RCC;
— irradiated RCC;
— irradiated leukocyte-depleted RCC;
— washed RCC.
The advantages of RBC transfusions are that:
— they rapidly increase hemoglobin levels in patients 
with anemia;
— they are effective regardless of anemia etiology. 
Cancer patients receiving a transfusion of blood
components are found to have:
— shorter overall survival time [6-10];
— the earlier occurrence of tumor relapse [10-12];
— higher mortality due to recurrence of the neoplastic 
disease [11, 13];
— a higher num ber of postoperative complications 
(including infections) [14-17];
— prolonged hospital stay [18];
— higher risk of developing lymphomas [19];
— higher risk of thromboembolic complications.
The reasons for the adverse effects of blood compo­
nents transfusions may be:
— changes that occur during the RBC storage;
— immunogenicity of blood cells;
— thrombogenicity of blood component;




— using less safe blood concentrates due to lower costs.
Table 2. Post-transfusion im m une-m ediated adverse reactions
Post-transfusion im m un e-m ed ia ted  adverse reactions
Early Delayed
A c u te  h e m o ly t ic  t ra n s fu s io n  re a c t io n  (AHTR) D e layed  h e m o ly t ic  t ra n s fu s io n  re a c t io n
T ra n s fu s io n -re la te d  a c u te  lu n g  in ju ry  (TRALI) T ra n s fu s io n -a s s o c ia te d  g r a f t  ve rs u s  h o s t d ise a se  (TA -G vH D )
F e b rile  n o n -h e m o ly t ic  t ra n s fu s io n  re a c t io n s  (FNHTR) P o s t- tra n s fu s io n  p u rp u ra  (PTP)
A n a p h y la c t ic  re a c t io n A l lo im m u n iz a t io n  to  b lo o d  ce ll a n t ig e n s
U r t ic a r ia  Im m u n o s u p p re s s io n
Due to the increasingly common use of immuno­
therapy with immune checkpoint inhibitors in cancer 
patients, the impact of blood component transfusions 
on the immune system should be taken into account. 
Cytokine release (including IL-6, IL-8, IL-10) in ­
duced by transfusion of blood components has proven 
pro-inflammatory and immunosuppressive effects, and, 
its clinically significant interaction with a mechanism 
of action of immunomodulating drugs cannot be ex­
cluded [20].
Therefore, RBC transfusions should not be used as 
a universal method of treating anemia in cancer patients 
and should be limited only to situations in which they 
are the only effective way to raise hemoglobin levels or 
are indications for immediate elimination or relief of 
anemia symptoms.
In addition, 2020 has already brought an addi­
tional problem in many countries (including Poland) 
related to a significant reduction in the availability of 
blood and its components due to the rapidly spread­
ing SARS-CoV-2 pandem ic and the need for their 
rational use.
Due to the possibility of a number of post-transfusion 
adverse reactions, including fatal ones (Tables 2 and 3), 
and taking into account that the m ajority of them  
are caused by the presence of leukocytes in blood 
com ponents, it is advisable to use prophylaxis by 
leukocyte dep le tion  in b lood  com ponents and/or 
X-ray irradiation.
Absolute indications to leukocyte-depleted RCC 
include [19]:
— transfusions in patients with previous non-hemolytic 
febrile reactions;
— transfusions in patients with previous TRALI;
— transfusions in patients with or suspected to have 
anti-HLA antibodies;
— prophylaxis of immunization with erythrocyte anti­
gens — multiple recipients (in the course of hemat­
opoietic malignancies or chronic renal failure);
— prophylaxis of immunization with HLA antigens;
• non-hemolytic febrile reactions,
• platelet transfusion refractoriness;
— prophylaxis of cytomegalovirus (CMV) infection.
Table 3. Post-transfusion non-im m une-m ediated adverse 
reactions
Post-transfusion n o n -im m u ne-m ed ia ted  adverse  
reactions
Early Delayed
N o n - im m u n e  h e m o ly s is H e m o s id e ro s is
T ra n s fu s io n  a sso c ia te d T ra n s m is s io n  o f  v ira l,  b a c te r ia l,
c ir c u la to ry  o v e r lo a d  (TACO) p ro to z o a l in fe c t io n s
Sepsis T ra n s m is s io n  o f  p r io n s
A ir  e m b o lis m
C itra te  in to x ic a t io n
Leukocyte depletion in blood components does not
prevent transfusion-associated graft versus host disease
(TA-GvHD) which is caused by donor lymphocytes. In
order to reduce the risk of TA-GvHD, irradiation of
RBC concentrates is necessary.
Absolute indication to irradiated RCC include [19]:
— relatedness (1st and 2nd degrees) between donor 
and recipient;
— HLA compatible blood components;
— immunodeficiency (especially with severe T-cell 
deficiency syndrome);
— transfusion of granulocyte concentrates;
— hem atopoietic cell transplant recipients — from 
the initiation of conditioning chemotherapy and/or 
radiotherapy to completion of GvHD prophylaxis 
related to the transplant, usually for about 3 months 
(autologous transplant) or 6 months (allogeneic 
transplant) after the transplant or until the blood 
lymphocyte count is above 109/L;
— chronic GvHD;
— autologous hematopoietic cells collection and within 
7 days prior to collection;
— immunosuppressive treatment;
— Hodgkin’s disease;
— treatment with purine analogues (e.g. fludarabine, 
cladribine, deoxycoformicin) or purine antagonists 
(bendamustine, clofarabine);
— treatment with alemtuzumab (anti-CD52).
Erythropoiesis stim ulating agents (ESA)
Erythropoiesis stimulating agents (ESAs) include:
— epoetin (alpha, beta, theta);
— darbepoetin alfa.
ESAs work by stimulating the receptors for eryth­
ropoietin.
Aim of ESA treatment
The use of ESA reduces the number of necessary 
transfusions, reduces the risk of post-transfusion adverse 
reactions, and improves the quality of life of patients 
with chemotherapy-induced anemia.
The target hemoglobin level, which obviates the need 
for RBC transfusion is approximately 12 g/dL. When 
using ESA a Hb level of 12 g/dL should not be exceeded.
According to the registered indications, ESAs can 
be used in patients with non-myeloid neoplasms with 
chemotherapy-induced anemia (CIA). In line with the 
ESMO recommendations, ESA can also be used in 
patients with myelodysplastic syndrome [21].
The use of ESA in patients with hypersensitivity to the 
drug and uncontrolled hypertension is not recommended.
All meta-analyses confirmed the effectiveness of 
ESA in reducing the frequency of blood transfusions, 
which is the main goal of ESA use in patients with CIA.
It is worth noting that ESA, unlike RBC concen­
tra te , has a positive effect on the immune system. 
Among other things, ESA reduces the expression of 
pro-inflammatory cytokine genes (IL-1/b, IL-6, IL-10, 
TNF-a), lowers the concentration of IL-1a and IL-6 and 
causes a decrease in the number of suppressive cells 
(CD8 + CD152+) [22-25].
Risk related to the use of ESAs
Using ESA increases the risk of:
1. Thromboembolic complications
It should be highlighted that many factors may 
contribute to the increased risk of thromboembolic 
complications in cancer patients. The most important of 
them are: high hematocrit, advanced patient’s age, pro­
longed immobilization, major surgery, multiple injuries, 
a history of thromboembolism, chronic heart failure and 
cancer type [26]. Remarkably higher risk of thrombo­
embolic events occurs in pancreatic and gastric cancer, 
and in multiple myeloma during immunomodulatory 
treatm ent [27, 28]. However, there is no convincing 
clinical evidence that the use of ESA further increases 
the risk of thromboembolic events in patients treated 
with lenalidomide or thalidomide. [29, 30].
Due to the lack of prospective randomized clinical 
trials (RCTs) proving that anticoagulation treatm ent 
reduces the risk of thromboembolic events in patients 
receiving ESA, and the conclusions from meta-ana- 
lyzes showing a relatively low risk of thromboembolic
Table 4. M odel o f risk assessment o f throm boem bolic  
complications in outpatients
Risk factors Points
G a s tr ic  ca n ce r, p a n c re a tic  c a n c e r 2
Lu n g  ca n ce r, b la d d e r  ca n ce r, te s t ic u la r  ca n ce r, k id n e y  
ca n ce r, ly m p h o m a
P la te le t c o u n t  b e fo re  c h e m o th e r a p y  >  3 5 0 ,0 0 0 /u L
H e m o g lo b in  leve l <  10  g /d L  or ESA use
L e u k o c y te  c o u n t  b e fo re  c h e m o th e ra p y  >  1 1 ,0 0 0 /ju L
BM I >  3 5  k g /m 2
H ig h  risk —  to ta l p o in ts  > 3 
In te rm e d ia te  risk  —  to ta l p o in ts  =  1 -2  
L ow  risk  —  to ta l p o in ts  =  0
Table 5. M odel o f risk assessment o f throm boem bolic  
complications in in patients treated stationary (authors 
modification)
Risk factors Points
A c t iv e  m a lig n a n t  t u m o r 3
H is to ry  o f  th ro m b o s is  (e x c lu d in g  
s u p e r f ic ia l th ro m b o s is )
M o b i l i t y  re s tr ic t io n s
T h ro m b o p h ilia
R e cen t (u p  to  a m o n th )  t ra u m a  o r  s u rg e ry
A g e  > 7 0  yea rs
H e a rt a n d /o r  lu n g  fa ilu re
M y o c a rd ia l in fa r c t  a n d /o r  is c h e m ic  s t ro k e
A c u te  in fe c t io n  a n d /o r  rh e u m a to lo g ic a l d ise a se
BM I >  3 0  k g /m 2
C u rre n t  h o rm o n e  t re a tm e n t
ESA use
H ig h  risk —  to ta l p o in ts  > 4
complications in patients treated with ESA according 
to the currently recognized indications, routine throm ­
boprophylaxis during treatm ent with ESA alone is not 
recommended [31].
However, other risk factors for thromboembolic 
complications in cancer patients should be considered 
and the adm inistration of ESA should be included 
when assessing individualized risk for each patient. The 
algorithms for calculating the risk indices for outpatients 
(example in Table 4 [32]) or hospitalized patients (ex­
ample — Table 5 [33]) may be helpful.
2. Hypertension — patients with chronic renal 
failure are particularly at risk
When ESAs are used in accordance with the registra­
tion and based on recommendations for the treatm ent 





when the Hb level is 12 g/dL or higher, then no adverse 
effect on overall survival is observed, and there is no 
evidence from clinical trials (neither single studies nor 
meta-analyzes) of a stimulating effect of ESAs on cancer 
progression or relapse [34-53].
Recommendations
1. Indications for the initiation of anemia treatment
In most cases of normovolemic anemia with Hb 
concentration above 7 g/dL, proper oxygenation of 
tissues is ensured without the need to activate adaptive 
mechanisms, provided that normal life activities are 
performed and do not require greater physical effort. 
Red blood cell transfusion in most people with Hb levels 
higher than 7 g/dL does not increase the amount of oxy­
gen delivered to the organs. In patients with symptoms 
of severe anemia (symptoms of ischemic heart disease, 
tachycardia, dyspnea, orthostatic hypotension, fatigue), 
red blood cell transfusion is indicated when the Hb 
concentration is lower than 8 g/dL. Majority of patients 
— even in a severe general state — tolerate Hb levels in 
the range of 7-10 g/dL well [54]. In general, the periop­
erative mortality rate in patients with preoperative Hb 
levels between 6 and 10 g/dL is not increased compared 
to patients with Hb levels above 10 g/dL. Moreover, 
there are reports that a liberal red blood cell transfusion 
strategy (Hb concentration < 10 g/dL) is associated 
with higher mortality compared to a restrictive strategy, 
in which the use of RBC is ordered only after the Hb 
concentration drops below 7-8 g/dL [55].
It should be emphasized that in the early stages of 
neoplastic disease, a statistically significant positive 
correlation was observed between RBC transfusion and 
shorter overall survival and higher mortality. According 
to the authors of these recommendations, there is a risk 
associated with RBC transfusions in the treatm ent of 
anemia in early-stage cancers. This is most likely due to 
the immunomodulatory effect of the transfused blood 
component, which suppresses the recipient’s immune 
system and weakens its cancer-controlling function.
If the Hb level is above 6 g/dL and there are no 
symptoms of severe anem ia requiring urgent RBC 
transfusion, it is recommended to diagnose the cause(s) 
of anemia and apply the procedures appropriate to the 
diagnosis (e.g., correct iron deficiency, stop bleeding, 
stop hemolysis). If the above procedure does not bring 
the expected results (increase in Hb level above 8 g/dL), 
the use of ESA can be considered (Figure 1). In patients 
receiving chemotherapy or combined chemoradiothera- 
py, ESA should be started at Hb levels < 10 g/dL if there 
are symptoms related to anemia. The use of ESA may be 
considered in selected asymptomatic patients receiving 
chemotherapy with Hb levels < 8 g/dL.
In patients with normal Hb levels before chemo­
therapy prophylactic use of ESA is not recommended.
There is no clear evidence that leukocyte-depleted 
RBC concentrate transfusions have a more favorable 
impact on the course of the neoplastic disease than blood 
cells without a reduced number of leukocytes. Howev­
er, due to the higher risk of post-transfusion adverse 
reactions related  to the presence of leukocytes in 
concentrates (febrile non-hemolytic transfusion reac­
tions, TRALI, immunization, CMV transmission), it is 
advisable to use leukocyte-depleted RBC concentrate 
in cancer patients who are expected to receive multiple 
transfusions of blood components.
2. Aim of anemia treatment
The aims of anemia treatm ent include:
— improvement or resolution of anemia symptoms;
— enabling anticancer treatment;
— improvement of quality of life, taking into ac­
count a patient’s life expectancy.
This goal should be achieved with the least invasive 
and safest treatm ent methods. Table 6 presents a com­




Due to very common elevated levels of hepcidin 
blocking the ferroportin responsible for the iron trans­
port from enterocytes into the blood in cancer patients, 
orally administered iron will not be effective. In these 
patients, iron should only be administered intravenously. 
Currently used iron preparations are safe and, in ac­
cordance with the recommendations of the European 
Medicines Agency, do not require a trial dose admin­
istration [56]. When choosing an iron preparation, the 
deficiency stage and the duration of infusion should be 
taken into account (Table 7). The recommended dose 
is 1000 mg as a single or divided dose.
ESA dosage
The starting dose for ESA is:
— epoetin  — 150 U/kg th ree  tim es p er w eek or
30,000 U/week;
— darbepoetin — 2.25 ;u,g/kg/week or 500 p.g/3 weeks.
A  preliminary evaluation of iron balance is neces­
sary and the use of ESA should only be started after 
any deficiencies have been corrected. It is advisable 
to monitor hemoglobin levels and iron stores during 
treatm ent [57]. In the case of iron deficiency, appro­
priate supplementation is necessary, but only by the 
intravenous route.
* l f  indicated
Figure 1. Algorithm for management of anemia in cancer patients. Hb —  hemoglobin; ESA —  erythropoiesis stimulating agent; 
RBC —  a concentrate of red blood cells
Table 6. Advantages and risks related to  specific methods o f anemia treatm ent
A dvantages Risks and lim ita tions
RBC t ra n s fu s io n s Q u ic k ly  re d u c e s  th e  s y m p to m s  o f  a n e m ia , 
re g a rd le s s  o f  its  ca u se , a n d  in c re a se s  th e  H b 
leve l
C an ca u se  m a n y  a d ve rse  re a c t io n s ,  in c lu d in g  fa ta l o n e s
R e q u ire  p re - tra n s fu s io n  te s ts
T h e  n e c e s s ity  o f  h o s p ita liz a t io n
H b c o n c e n tr a t io n  c a n n o t  be  k e p t  o n  s ta b le  leve l
A d v e rs e  e f fe c t  o n  th e  im m u n e  s y s te m  ( im m u n o s u p p re s s io n ,
p o s s ib le  in te r a c t io n  w i t h  im m u n o th e ra p y )
ESA P o s s ib ility  o f  o u tp a t ie n t  t re a tm e n t In c re a se d  r isk  o f  th ro m b o e m b o lic  c o m p lic a t io n s
S ta b le  H b  leve ls  d u r in g  t re a tm e n t T h e  t im e  re q u ire d  t o  a c h ie v e  a t re a tm e n t  e f fe c t
B e n e fic ia l e f fe c t  o n  th e  im m u n e  sys te m In d ic a t io n s  lim ite d  t o  th e  g ro u p  o f  p a t ie n ts  re c e iv in g  
c h e m o th e ra p y  o r  c h e m o ra d io th e ra p y
Im p ro v in g  p a t ie n ts ' q u a l i t y  o f  li fe M a y  b e  in e ffe c t iv e  in  s o m e  p a t ie n ts
Table 7. Dosages and m inim um  infusion tim e fo r iron preparations.
Iro n  p repara tio n M axim um  dose M in im u m  infusion tim e
G lu c o n a te 1 2 5  m g 6 0  m in
S a c c h a r id e 2 0 0 - 5 0 0  m g 3 0 - 2 1 0  m in
D e x tra n D if fe re n t 2 4 0 - 3 6 0  m in
D e r is o m a lto s id e 2 0  m g /k g 15  m in  ( fo r  a d o s e  <  1 0 0 0  m g )
C a rb o x y m a to s id e  2 0  m g /k g  to  1 0 0 0  m g  15  m in
ESA doses should be reduced by approximately 
25-50% if the hemoglobin concentration rises to levels 
preventing red blood cell transfusions or increases by 
more than 2 g/dL within 4 weeks.
It is recommended to thoroughly inform patients 
about the planned use of ESA together with comprehen­
sive information on the purpose and potential adverse 
reactions associated with the treatm ent (especially 
thromboembolic complications). It is also recommend­
ed to inform the primary care physician about the use 
of ESA.
Except patients receiving epoetin theta (deliber­
ately administered at a low initial dose), increases in 
ESA doses and changes to other ESA preparation in 
unresponsive patients within 4-8 weeks are not rec­
ommended. ESA treatm ent should be discontinued in 
patients who have not demonstrated at least initial Hb 
response after this period.
ESA discontinuation is also recom m ended after 
a maximum of 4 weeks after chemotherapy completion 
and in the case of the appearance of neutralizing an­
ti-ESA antibodies.
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